C3N-03425
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 64.54209446
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03051 | — | cohortSQ1 | 0.886 |
| 2 | SRR8942992 | — | — | 0.859 |
| 3 | TCGA-G2-A2ES-01A-11R-A180-07 | — | — | 0.846 |
| 4 | BS_996ZS2A4 | ATRT | — | 0.842 |
| 5 | TCGA-XF-A8HE-01A-11R-A36F-07 | — | — | 0.838 |
| 6 | R261 | — | — | 0.828 |
| 7 | BS_S5P8VTN5 | high-grade glioma | — | 0.822 |
| 8 | TCGA-63-A5MR-01A-31R-A27Q-07 | — | cohortSQ1 | 0.821 |
| 9 | TCGA-EW-A1P4-01A-21R-A144-07 | — | E | 0.821 |
| 10 | TCGA-E2-A14Y-01A-21R-A12D-07 | — | E | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.340 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |